Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kristin M. McCabe is active.

Publication


Featured researches published by Kristin M. McCabe.


Kidney International | 2013

Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease

Kristin M. McCabe; Sarah L. Booth; Xueyan Fu; Navid Shobeiri; Judith J. Pang; Michael A. Adams; Rachel M. Holden

The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease, with vascular calcification being a key modifier of disease progression. A local regulator of vascular calcification is vitamin K. This γ-glutamyl carboxylase substrate is an essential cofactor in the activation of several extracellular matrix proteins that inhibit calcification. Warfarin, a common therapy in dialysis patients, inhibits the recycling of vitamin K and thereby decreases the inhibitory activity of these proteins. In this study, we sought to determine whether modifying vitamin K status, either by increasing dietary vitamin K intake or by antagonism with therapeutic doses of warfarin, could alter the development of vascular calcification in male Sprague-Dawley rats with adenine-induced CKD. Treatment of CKD rats with warfarin markedly increased pulse pressure and pulse wave velocity, as well as significantly increased calcium concentrations in the thoracic aorta (3-fold), abdominal aorta (8-fold), renal artery (4-fold), and carotid artery (20-fold). In contrast, treatment with high dietary vitamin K1 increased vitamin K tissue concentrations (10-300-fold) and blunted the development of vascular calcification. Thus, vitamin K has an important role in modifying mechanisms linked to the susceptibility of arteries to calcify in an experimental model of CKD.


Endocrinology | 2012

Perinatal iron deficiency combined with a high-fat diet causes obesity and cardiovascular dysregulation.

Stephane L. Bourque; Marina Komolova; Kristin M. McCabe; Michael A. Adams; Kanji Nakatsu

Consumption of a high-fat Western diet (WD) and the resultant obesity is linked to a number of chronic pathologies, including cardiovascular dysregulation. The purpose of the present study was to determine whether perinatal iron deficiency (PID) added to the consumption of a WD would precipitate an obese phenotype with exacerbated metabolic and cardiovascular outcomes in adult offspring. Female Sprague Dawley rats were fed either a control (225 mg/kg Fe) or an iron-restricted diet (3-10 mg/kg Fe) prior to and throughout gestation. At birth, all dams were fed an iron-replete diet. At weaning, offspring were fed a normal diet or WD for up to 21 wk. Hemodynamics and locomotor activity were assessed by radiotelemetry starting at 15 wk of age. Iron restriction during pregnancy caused severe anemia in dams and offspring, resulting in 15% lower birth weights in the offspring. PID offspring fed the WD had greater caloric intake and exhibited reduced locomotor activity compared with their normal diet-fed littermates; no such effects were observed in normal iron control offspring. Despite having a similar effect on serum lipid profiles, consumption of the WD had a greater impact on body weight in the PID group, and this weight gain was due largely to visceral adipose tissue accumulation. A significant correlation between visceral adipose tissue weight and mean arterial pressure was observed in the PID offspring but not in controls. These observations demonstrate that PID predisposes offspring to an enhanced response to WD characterized by increased fat accumulation and cardiovascular dysregulation.


Nutrients | 2013

Vitamin K status in chronic kidney disease.

Kristin M. McCabe; Michael A. Adams; Rachel M. Holden

The purpose of this review is to summarize the research to date on vitamin K status in chronic kidney disease (CKD). This review includes a summary of the data available on vitamin K status in patients across the spectrum of CKD as well as the link between vitamin K deficiency in CKD and bone dynamics, including mineralization and demineralization, as well as ectopic mineralization. It also describes two current clinical trials that are underway evaluating vitamin K treatment in CKD patients. These data may inform future clinical practice in this population.


Journal of Pharmacology and Experimental Therapeutics | 2015

Magnesium Modifies the impact of Calcitriol Treatment on Vascular Calcification in Experimental Chronic Kidney Disease

Jason G.E. Zelt; Kristin M. McCabe; Bruno Svajger; Henry Barron; Kim Laverty; Rachel M. Holden; Michael A. Adams

Chronic kidney disease (CKD) patients are commonly treated with vitamin D analogs, such as calcitriol. Recent epidemiologic evidence revealed a significant interaction between vitamin D and magnesium, since an inverse relationship between vitamin D levels and mortality mainly occurs in patients with a high magnesium intake. The aim of the study was to assess the mechanisms involved by determining whether magnesium alone or combined with calcitriol treatments differentially impacts vascular calcification (VC) in male Sprague-Dawley rats with adenine-induced CKD. Treatment with moderate doses of calcitriol (80 μg/kg) suppressed parathyroid hormone to near or slightly below control levels. Given alone, this dose of calcitriol increased the prevalence of VC; however, when magnesium was given in combination, the severity of calcification was attenuated in the abdominal aorta (51% reduction), iliac (44%), and carotid arteries (46%) compared with CKD controls. The decreases in vascular calcium content were associated with a 20–50% increase in vascular magnesium. Calcitriol treatment alone significantly decreased TRPM7 protein (↓ to ∼11%), whereas the combination treatment increased both mRNA (1.7×) and protein (6.8×) expression compared with calcitriol alone. In summary, calcitriol increased VC in certain conditions, but magnesium prevented the reduction in TRPM7 and reduced the severity of VC, thereby increasing the bioavailable magnesium in the vascular microenvironment. These findings suggest that modifying the adverse effect profile of calcitriol with magnesium may be a plausible approach to benefiting the increasing number of CKD patients being prescribed calcitriol.


American Journal of Nephrology | 2017

Vitamin K Metabolism in a Rat Model of Chronic Kidney Disease

Kristin M. McCabe; Sarah L. Booth; Xueyan Fu; Emilie Ward; Michael A. Adams; Rachel M. Holden

Background: Patients with chronic kidney disease (CKD) have very high levels of uncarboxylated, inactive, extra-hepatic vitamin K-dependent proteins measured in circulation, putting them at risk for complications of vitamin K deficiency. The major form of vitamin K found in the liver is phylloquinone (K1). Menaquinone-4 (MK-4) is the form of vitamin K that is preferentially found in extra-hepatic tissues. Methods: In the present study, we assessed tissue concentrations of K1 and MK-4 and the expression of vitamin K-related genes in a rat model of adenine-induced CKD. Results: It was found that rats with both mild and severe CKD had significantly lower amounts of K1 measured in liver, spleen and heart and higher levels of MK-4 measured in kidney cortex and medulla. All animals treated with high dietary K1 had an increase in tissue levels of both K1 and MK-4; however, the relative increase in K1 differed suggesting that the conversion of K1 to MK-4 may be a regulated/limiting process in some tissues. There was a decrease in the thoracic aorta expression of vitamin K recycling (Vkor) and utilization (Ggcx) enzymes, and a decrease in the kidney level of vitamin K1 to MK-4 bioconversion enzyme Ubiad1 in CKD. Conclusion: Taken together, these findings suggest that CKD impacts vitamin K metabolism, and this occurs early in the disease course. Our findings that vitamin K metabolism is altered in the presence of CKD provides further support that sub-clinical vitamin K deficiency may represent a modifiable risk factor for vascular and bone health in this population.


The Journal of Sexual Medicine | 2014

Calcification of the Internal Pudendal Artery and Development of Erectile Dysfunction in Adenine‐Induced Chronic Kidney Disease: A Sentinel of Systemic Vascular Changes

M. Tina Maio; Kristin M. McCabe; Cynthia M. Pruss; Judith J. Pang; Kimberly Laverty; Rachel M. Holden; Michael A. Adams

INTRODUCTION Chronic kidney disease (CKD), erectile dysfunction (ED), and cardiovascular disease share common vascular etiologies and risk factors. AIM Using a rat model, this is the first study to characterize the consequences of CKD in the onset and development of ED associated with differential regional vascular calcification and circulatory changes. METHODS Stable CKD was generated at 3 weeks in male Sprague-Dawley rats given dietary adenine and progressed until 7 weeks. Mineral content and morphometry were assessed in the internal pudendal arteries (IPAs), thoracic aorta, and carotid artery. Endothelial function was determined via changes in serum von Willebrand factor (VWF) and endothelium-dependent relaxation of the thoracic aorta. RESULTS In severe CKD rats, calcium and phosphate content in all arteries increased, and pulse wave velocity was elevated. Distal IPA segments, in particular, were the first to calcify, but penile tissue per se did not. CKD rats had endothelial dysfunction, as indicated by a decrease in acetylcholine-mediated relaxation (∼40%) and an increase in serum VWF (∼40%), as well as increased lumen diameter (20%) of the distal IPA. Erectile function, assessed using a centrally acting dopaminergic agent, was significantly impaired by 7 weeks (∼40%). CONCLUSIONS In CKD, the distal IPA appears to be more susceptible to vascular dysfunction and calcification. Additionally, the onset of ED may be an important sentinel of impending systemic vascular disease. To confirm this concept, future experimental and clinical studies will need to examine a range of vessel types and the use of supplementary methods to assess erectile function.


Canadian journal of kidney health and disease | 2015

Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease

Rachel M. Holden; Sarah L. Booth; Andrew Day; Catherine M. Clase; Deborah Zimmerman; Louise Moist; M. Kyla Shea; Kristin M. McCabe; Sophie A. Jamal; Sheldon W. Tobe; Jordan Weinstein; Rao Madhumathi; Michael A. Adams; Daren K. Heyland


Nephrology Dialysis Transplantation | 2016

MP357VASCULAR CALCIFICATION OF THE PUDENDAL ARTERY IS A SENTINEL FOR ELEVATED PULSE WAVE VELOCITY

Paul S. Jeronimo; Jason G.E. Zelt; Kristin M. McCabe; Maria Tina Maio Twofoot; Kimberly Laverty; Mandy Turner; Rachel M. Holden; Michael A. Adams


Nephrology Dialysis Transplantation | 2016

MP347CALCITRIOL ALTERS THE PATHOLOGICAL PHENOTYPE ASSOCIATED WITH LEFT VENTRICULAR HYPERTROPHY IN AN EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE

Mandy Turner; Kristin M. McCabe; Jason G.E. Zelt; Kimberly Laverty; Rachel M. Holden; Michael A. Adams


Nephrology Dialysis Transplantation | 2015

SP411COMBINED MAGNESIUM AND CALCITRIOL SUPPLEMENTATION ATTENUATES VASCULAR CALCIFICATION SEVERITY IN EXPERIMENTAL CHRONIC KIDNEY DISEASE

Jason G.E. Zelt; Kristin M. McCabe; Bruno Svajger; Henry Barron; Emilie Ward; Kimberly Laverty; Rachel M. Holden; Michael A. Adams

Collaboration


Dive into the Kristin M. McCabe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge